FDA approves Zontivity, Merck heart attack prevention drug, for high-risk patients
from Medical Daily
The Food and Drug Administration has announced its approval for the Merck heart attack and stroke prevention drug, Zontivity, for high-risk patients who have never suffered from a number of prior conditions. Zontivity (vorapaxar) tablets are the first in a new class of drug known as protease-activated receptor-1 (PAR-1) antagonists.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063